Core Insights - The company reported a revenue of RMB 393 million for the six months ending June 30, 2025, representing an 8.4% year-on-year increase [1] - Gross profit remained relatively stable at RMB 283 million, showing no significant change compared to the previous period [1] - Net profit attributable to the parent company decreased by 66.7% to RMB 20.514 million, with basic earnings per share at RMB 0.04 [1] - The increase in revenue was primarily driven by a 15.9% growth in sales of key products (博优诺®, 博优倍®, and 博洛加®), totaling RMB 385.3 million [1]

Core Viewpoint - The company reported a revenue of 393 million RMB for the six months ending June 30, 2025, reflecting an 8.39% year-on-year increase, while the net profit attributable to shareholders decreased by 66.74% to 20.514 million RMB [1] Revenue Performance - The revenue increase was primarily driven by the sales growth of products (Bo Younuo, Bo Youbei, and Bo Luojia), which rose by 15.9% to 385 million RMB compared to the six months ending June 30, 2024 [1]

Core Points - The company reported a revenue of 393 million RMB for the six months ending June 30, 2025, representing an increase of 8.39% year-on-year [1] - Shareholder profit attributable to the company was 20.514 million RMB, a decrease of 66.74% compared to the previous year [1] - Basic earnings per share were 0.04 RMB [1] Revenue Analysis - The increase in revenue was primarily driven by the sales growth of products (博优诺®, 博优倍®, and 博洛加®), which rose by 15.9% to 385 million RMB compared to the six months ending June 30, 2024 [1]

Financial Performance - For the six months ending June 30, 2025, Shandong Boan Biotechnology reported revenue of approximately RMB 393.4 million, an increase of about RMB 30.5 million or 8.4% compared to RMB 362.9 million for the same period in 2024[2]. - The company recorded a profit before tax of RMB 20.5 million, down from RMB 61.7 million in the previous year[8]. - The total comprehensive income for the period was RMB 20.4 million, compared to RMB 61.6 million for the same period in 2024[8]. - Basic and diluted earnings per share for the period were RMB 0.04, down from RMB 0.12 in the previous year[8]. - Revenue increased by 8.4% to RMB 393.4 million, with product sales rising by 15.9% to RMB 385.3 million[42]. - The company recorded revenue of RMB 393.4 million and a net profit of RMB 20.5 million for the six months ending June 30, 2025, marking the third consecutive reporting period of positive profitability[90]. Cost and Expenses - The sales cost for the same period was RMB 110.8 million, representing approximately 28.2% of total revenue, up from 22.1% in the previous year[3]. - Sales and distribution expenses increased to RMB 159.8 million, a rise of RMB 25.6 million or 19.1% from RMB 134.2 million in the prior year[5]. - Research and development expenses were approximately RMB 58.6 million, a decrease of about RMB 27.2 million compared to RMB 85.8 million for the same period in 2024[6]. - Other income and gains decreased to RMB 2.6 million, down approximately RMB 33.5 million from RMB 36.1 million in the previous year, primarily due to a reduction in government grants[99]. - Financial costs increased by approximately RMB 6.9 million to RMB 19.5 million, representing a year-on-year growth of 54.8%[103]. Assets and Liabilities - As of June 30, 2025, total non-current assets amounted to RMB 1,895,008 thousand, a decrease from RMB 1,996,079 thousand as of December 31, 2024, reflecting a decline of about 5.1%[9]. - Current assets totaled RMB 956,280 thousand as of June 30, 2025, down from RMB 1,438,554 thousand at the end of 2024, indicating a decrease of approximately 33.5%[9]. - The company's total liabilities as of June 30, 2025, were RMB 1,401,501 thousand, compared to RMB 1,297,250 thousand at the end of 2024, marking an increase of about 8.0%[10]. - Net assets increased to RMB 2,033,132 thousand as of June 30, 2025, up from RMB 1,644,038 thousand at the end of 2024, representing a growth of approximately 23.7%[10]. - The company’s cash and cash equivalents rose significantly to RMB 659,966 thousand as of June 30, 2025, compared to RMB 198,867 thousand at the end of 2024, reflecting an increase of about 231.5%[9]. Trade Receivables and Payables - The company’s trade receivables increased to RMB 527,069 thousand as of June 30, 2025, compared to RMB 453,604 thousand at the end of 2024, representing an increase of about 16.2%[9]. - Trade payables amounted to RMB 136,110,000 as of June 30, 2025, slightly up from RMB 125,137,000 at the end of 2024, reflecting an 8% increase[28]. - The group maintained strict control over trade receivables, with a significant portion (RMB 251,224,000) being within three months overdue as of June 30, 2025[27]. - The group reported a net impairment of trade receivables of RMB 7,070,000 for the six months ended June 30, 2025, compared to RMB 2,168,000 in 2024[25]. Product Development and Pipeline - The company has four approved products in its portfolio and is developing multiple innovative biopharmaceuticals with international intellectual property protection[40]. - The company is actively engaged in the development of a trial drug that is currently under review for market approval[40]. - Significant achievements have been made in pipeline development, sales and marketing, manufacturing, and business collaborations since the beginning of 2025[41]. - The product portfolio includes four approved products, one candidate in the BLA review stage, and six candidates in clinical trials, focusing on major therapeutic areas such as oncology, autoimmune diseases, and ophthalmology, which have significant unmet needs in both China and overseas markets[47]. - The company has developed a balanced product pipeline aimed at achieving commercialization in the short term while driving sustainable long-term growth[47]. Market and Competitive Position - The company was included in the MSCI Global Small Cap Index in May 2025, reflecting recognition of its high growth potential[45]. - The company has established a broad distribution network with over 191 distributors, reaching more than 3,112 target hospitals and institutions in China[82]. - The company has partnered with Qingdao Guoxin Pharmaceutical for exclusive promotion of 博优倍® in mainland China since 2023[85]. - The company has granted exclusive rights to Eucan for the promotion of BA9101 in mainland China post-launch[86]. Employee and Management - As of June 30, 2025, the R&D team consists of 254 experienced employees, covering various research functions with most having over seven years of experience[76]. - The total compensation for key management personnel was RMB 10,459,000 for the six months ended June 30, 2025, down from RMB 15,098,000 in the same period of 2024[38]. - The company employed a total of 714 employees, down from 777 employees as of June 30, 2024[115]. - Employee costs for the six months ended June 30, 2025, were approximately RMB 61.6 million, compared to RMB 86.4 million for the same period in 2024, reflecting a decrease of about 29%[115]. Corporate Governance and Compliance - The company has adopted a corporate governance code and has complied with all applicable provisions, with one exception regarding the separation of roles between the Chairman and CEO[121][122]. - The audit committee has reviewed the accounting principles and policies adopted by the group for the six months ended June 30, 2025, and recommended the same to the board[125]. - The company has not purchased, sold, or redeemed any of its listed securities during the six months ended June 30, 2025[124].

格隆汇8月15日丨博安生物(06955.HK)宣布，本公司将于2025年8月27日（星期三）举行董事会会议，藉 以（其中包括）批准本公司截至2025年6月30日止的中期业绩及其发布，并考虑派发中期股息（如 有）。 ...

（於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6955） 董事會會議通告 山東博安生物技術 股份有限公司（「本公司」）董事會（「董事會」）謹 此 宣 佈，本 公 司將於二零二五年八月二十七日（星 期 三）舉 行 董 事 會 會 議，藉 以（其 中 包 括）批 准 本 公 司 截 至 二 零 二 五 年 六 月 三 十 日 止 之 中 期 業 績 及 其 發 佈，並 考 慮 派 發 中 期股息（如 有）。 山東博安生物技術股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Shandong Boan Biotechnology Co., Ltd. 山東博安生物技術股份有限公司 承董事會命 主 席、首 席 執 行 官 及 執 行 董 事 姜 華 中 華 人 民 共 和 國，煙 台，二 零 二 五 年 八 月 十 五 日 於 本 公 告 日 ...

香港联交所最新资料显示，8月14日，博安生物(06955)股东将股票存入Merrill Lynch Far East Limited， 存仓市值8.3亿港元，占比8.36%。 博安生物公告，配售事项于2025年8月14日落实完成。合共4800万股新股份(相当于经配发及发行配售股 份扩大的已发行股份总数约7.71%)已按配售价每股配售股份16.42港元配售予不少于六名承配人。公司 就配售事项收取的所得款项净额合共约为7.80亿港元。 ...

博安生物公告，配售事项于2025年8月14日落实完成。合共4800万股新股份(相当于经配发及发行配售股 份扩大的已发行股份总数约7.71%)已按配售价每股配售股份16.42港元配售予不少于六名承配人。公司 就配售事项收取的所得款项净额合共约为7.80亿港元。 智通财经APP获悉，香港联交所最新资料显示，8月14日，博安生物(06955)股东将股票存入Merrill Lynch Far East Limited，存仓市值8.3亿港元，占比8.36%。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 山東博安生物技術股份有限公司 呈交日期： 2025年8月14日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06955 | 說明 H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（ ...

博安生物(06955)发布公告，配售事项于2025年8月14日落实完成。合共4800万股新股份(相当于经配发及 发行配售股份扩大的已发行股份总数约7.71%)已按配售价每股配售股份16.42港元配售予不少于六名承 配人。公司就配售事项收取的所得款项净额合共约为7.80亿港元。 ...